Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.
Triumvira Immunologics has raised $45.0M in total funding. The most recent round was Series A. The last funding was announced in March 2022.
Triumvira Immunologics's investors include B Capital, Northpond Ventures, Oceanpine Capital, Leaps by Bayer, Viva Biotech.
Triumvira Immunologics is headquartered in Austin, United States.
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.
Triumvira Immunologics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Triumvira Immunologics — Funding & Investors." VCBacked, March 17, 2022, https://www.vcbacked.co/company/triumvira-immunologics. Accessed August 14, 2026.
VCBacked. (2022). Triumvira Immunologics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/triumvira-immunologics
{{cite web |title=Triumvira Immunologics — Funding & Investors |url=https://www.vcbacked.co/company/triumvira-immunologics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated